IDH1 inhibitors have made great progress in the treatment of acute myeloid leukemia and glioma, but further research is needed to confirm their clinical efficacy in other tumors.
Hsp90 inhibitors are substances that inhibit the activity of the Hsp90 heat shock protein. They have therapeutic benefit in treating various types of malignancies, as Hsp90 stabilizes a variety of proteins required for cancer cell survival.
Due to HDAC’s fundamental role in gene expression and its different effects on histones and non-histones, HDAC has become an ideal target for the treatment of various malignant tumors. HDAC inhibitors are considered one of the most promising anti-cancer drugs.
HIV-1 protease inhibitors are a type of medication used to treat HIV by blocking the virus from entering certain cells in the body and making copies of itself.
HIV-1 integrase inhibitors block the catalytic activity of integrase to prevent the integration of viral DNA into the human genome, thereby preventing HIV virus replication.
HDAC6 inhibitors are effective chemotherapy agents that modulate protein acetylation, boost p21 gene expression, and hinder tumor growth through cell differentiation or apoptosis.
IL-6 inhibitors work by blocking the binding of IL-6 to the IL-6 receptor, inhibiting the signal transduction of IL-6, and thereby reducing the inflammatory response in patients. Several IL-6 inhibitors have been approved for use worldwide.